Long-term use of low-dose spironolactone in spontaneously hypertensive rats: Effects on left ventricular hypertrophy and stiffness

Pharmacological Reports

Volumn 63, Issue 4, 2011, Pages 975-982

  Baldo, Marcelo P ^a   Forechi, Ludimila ^a   Morra, Elis A S ^a   Zaniqueli, Divanei ^a   Machado, Rebeca C ^a   Lunz, Wellington ^a   Rodrigues, Sérgio L ^a   Mill, JoséGeraldo ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Hypertension; Spironolactone; Ventricular hypertrophy; Ventricular stiffness

Indexed keywords

SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OVERLOAD; HYPERTENSION; LEFT VENTRICULAR WALL STIFFNESS; LOW DRUG DOSE; NONHUMAN; PLETHYSMOGRAPHY; PRESSURE VOLUME CURVE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE; SYSTOLIC BLOOD PRESSURE; WISTAR RAT;

EID: 80053380047     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70613-2     Document Type: Article

References (30)

1. Avanza AC Jr, El Aouar LM, Mill JG: Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arq Bras Cardiol, 2000, 74, 111-117.
2. Baldo MP, Zaniqueli D, Forechi L, Machado RC, Rodrigues SL, Mill JG: Effect of spironolactone in adult spontaneously hypertensive rats submitted to high salt intake. Clinics, 2011, 66, 477-482.
3. Baumann M, Hermans JJR, Janssen BJA, Peutz-Kootstra C, Witzke O, Heemann U, Smits JFM, Boudier HAJS: Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. J Hypertens, 2007, 25, 2504-2511. (Pubitemid 350060390)
4. Bos R, Mougenot N, Findji L, Médiani O, vanhoutte PM, Lechat P: Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. J Cardiovasc Pharmacol, 2005, 45, 8-13. (Pubitemid 40039749)
5. Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res, 1992, 26, 671-677.
6. Cabassi A, Dancelli S, Pattoneri P, Tirabassi G, Quartieri F, Moschini L, Cavazzini S et al.: Characterization of myocardial hypertrophy in prehypertensive spontaneously hypertensive rats: interaction between adrenergic and nitrosative pathways. J Hypertens, 2007, 25, 1719-1730. (Pubitemid 47056581)
7. Cabassi A, Vinci S, Calzolari M, Bruschi G, Borghetti A: Regional sympathetic activity in prehypertensive phase of spontaneously hypertensive rats. Life Sci, 1998, 62, 1111-1118. (Pubitemid 28085432)
8. Calhoun DA: Low-dose aldosterone blockade as a new treatment paradigm for controlling resistance hypertension. J Clin Hypertens, 2007, 9, 19-24.
9. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S et al.: Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism. A prospective clinical study. Hypertension, 2010, 55, 1137-1142.
10. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S et al.: Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation, 2005, 112, 2940-2945. (Pubitemid 41612295)
11. Kambara A, Holycross BJ, Wung P, Schanbacher B, Ghosh S, McCune SA, Bauer JA, Kwiatkowski P: Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. J Cardiovasc Pharmacol, 2003, 41, 830-837. (Pubitemid 36706129)
12. Konishi A, Tazana C, Miki Y, Darnel AD, Suzuki T, Ohta Y, Suzuki T et al.: The possible roles of mineralocorticoid receptor and 11β- hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. J Ster Biochem Mol Biol, 2003, 85, 439-442. (Pubitemid 37011119)
13. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F: Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation, 2005, 111, 420-427. (Pubitemid 40204425)
14. Maron BA, Leopold JA: Aldosterone receptor antagonists. Effective but often forgotten. Circulation, 2010, 121, 934-939.
15. Mill JG, Milanez MC, Resende MM, Gomes MGS, Leite CM: Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clin Exp Pharmacol Physiol, 2003, 30, 739-744. (Pubitemid 37330520)
16. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y et al.: Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Heart Circ Physiol, 2007, 292, 946-954.
17. Okoshi MP, Yan X, Okoshi K, Nakayama M, Schldt AJT, O'Connell TD, Simpson PC, Lorell BH: Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail, 2004, 10, 511-518.
18. Otsuka S, Sugano M, Makino N, Sawada S, Hata T, Niho Y: Interaction of mRNAs for angiotension II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats. Hypertension, 1998, 32, 467-472. (Pubitemid 28429135)
19. Pitt B, Reichek N, Willenbrock R, Zannad F, Pjillips RA, Roniker B, Kleiman J et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4Eleft ventricular hypertrophy study. Circulation, 2003, 108, 1831-1838. (Pubitemid 37296092)
20. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med, 1999, 341, 709-717. (Pubitemid 29407370)
21. Resende MM, Kauser K, Mill JG: Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats. Life Sci, 2006, 78, 3066-3073.
22. Rocha WA, Lunz W, Baldo MP, Pimentel EB, Dantas EM, Rodrigues SL, Mill JG: Kinetics of cardiac and vascular remodeling by spontaneously hypertensive rats after discontinuation of long-term captopril treatment. Braz J Med Biol Res, 2010, 43, 390-396.
23. Susic D, Varagic J, Ahn J, Matavelli L, Frohlich ED: Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol, 2007, 292, 175-179.
24. Susic D, Varagic J, Ahn J, Matavelli LC, Frohlich ED: Beneficial cardiovascular actions of eplerenone in the spontaneously hypertensive rat. J Cardiovasc Pharmacol Ther, 2005, 10, 197-203. (Pubitemid 41376978)
25. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation, 1990, 82, 1730-1736. (Pubitemid 20367976)
26. Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiol Rev, 1999, 79, 215-262.
27. Takeda Y, Yoneda T, Demura M, Miyamori I, Mubuchi H: Cardiac aldosterone production in genetically hypertensive rats. Hypertension, 2000, 36, 495-500.
28. Varagic J, Frohlich ED: Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol, 2002, 34, 1435-1442. (Pubitemid 35373666)
29. Veliotes DGA, Woodiwiss AJ, Deftereos DAJ, Gray D, Osadchii O, Norton GR: Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by β-adrenoreceptor activation. Hypertension, 2005, 45, 914-920. (Pubitemid 40628937)
30. Wright JW, Mizutani S, Harding JW: Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev, 2008, 13, 367-375.